Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1961 to 1970 of 2607 total matches.

Mifepristone (Mifeprex) Label Changes

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016  (Issue 1493)
of intrauterine pregnancy.1 It has generally been used with the prostaglandin analog misoprostol (Cytotec ...
The FDA has approved several significant changes in the labeling of mifepristone (Mifeprex – Danco), an oral antiprogestin that has been used in the US for more than 15 years for termination of intrauterine pregnancy. It has generally been used with the prostaglandin analog misoprostol (Cytotec, and generics).
Med Lett Drugs Ther. 2016 Apr 25;58(1493):55-6 |  Show IntroductionHide Introduction

Eflornithine (Iwilfin) for High-Risk Neuroblastoma (online only)

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
and they account for ~15% of all pediatric cancer deaths.1 Eflornithine is the first drug to be approved ...
Eflornithine (Iwilfin – US WorldMeds), an oral ornithine decarboxylase inhibitor, has been approved by the FDA to reduce the risk of relapse in children and with high-risk neuroblastoma who had at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy. About 40-50% of neuroblastoma cases are classified as high-risk and they account for ~15% of all pediatric cancer deaths. Eflornithine is the first drug to be approved to reduce the risk of relapse in children with high-risk neuroblastoma. Eflornithine was previously available in the US...
Med Lett Drugs Ther. 2024 May 13;66(1702):e81-2   doi:10.58347/tml.2024.1702f |  Show IntroductionHide Introduction

Conjugated Haemophilus Influenzae Type b Vaccine

   
The Medical Letter on Drugs and Therapeutics • Apr 22, 1988  (Issue 764)
in less than 1% of vaccinees. When the vaccine was given with DTP or inactived polio vaccines, adverse ...
A new Haemophilus influenzae type b capsular polysaccharide vaccine conjugated with diphtheria toxoid (ProHIBiT - Connaught) was recently marketed in the USA. It is being promoted as a replacement for older, unconjugated H. influenzae vaccines (b- Capsa I; Hibimune; HibVAX) previously reviewed in The Medical Letter (Volume 27, page 61, 1985).
Med Lett Drugs Ther. 1988 Apr 22;30(764):47-8 |  Show IntroductionHide Introduction

Extracorporeal Shock-Wave Lithotripsy for Gallbladder Stones

   
The Medical Letter on Drugs and Therapeutics • Feb 10, 1989  (Issue 785)
treated patients also took oral gallstone-dissolving drugs (KA Hood et al, Lancet, 1:1322, 1988). Stones ...
Shock-wave generators like those now widely used to disintegrate urinary tract stones (Medical Letter, 27:72, 1985) have recently also been tried for treatment of radiolucent gallbladder stones. Three different types of lithotripsy devices, manufactured by at least eight different companies, are being used to treat gallbladder stones in multicenter trials in many locations in the USA. None of these devices has been approved for marketing by the US Food and Drug Administration.
Med Lett Drugs Ther. 1989 Feb 10;31(785):9-10 |  Show IntroductionHide Introduction

Nitroglycerin Patches - Do They Work?

   
The Medical Letter on Drugs and Therapeutics • Jul 14, 1989  (Issue 796)
. NITROGLYCERIN PATCHES Dose 1 (mg) Product Patch Size (sq cm) Cost 2 2.5 Minitran (3M Riker) 3.3 $ 29.00 3 ...
Transdermal nitroglycerin products commercially available in the USA are listed in the table below. These patches, which look like adhesive bandages, are often applied over the precordium, but they can be attached to any hairless area of the skin, except distal parts of the extremities. Individual patients vary in their absorption of nitroglycerin from the skin; the amounts delivered (the doses) are average figures.
Med Lett Drugs Ther. 1989 Jul 14;31(796):65-6 |  Show IntroductionHide Introduction

Adjuvant Chemotherapy of Early Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • May 18, 1990  (Issue 818)
that patients with tumors less than 1 cm in diameter have an excellent prognosis without any adjuvant therapy ...
The most important prognostic variable in early breast cancer is axillary lymph node involvement. Based on past experience, after 10 years about 70% of node-negative patients will be alive and apparently free of disease; about 30% will have relapsed or died. Patients with positive nodes may have a 30% to 60% relapse rate, depending on the number of positive nodes and other prognostic factors, such as the presence of estrogen receptors (IC Henderson et al, in VT DeVita, Jr et al, eds, Cancer: Principles and Practice of Oncology, 3rd ed, Philadelphia:Lippincott, 1989, p 1197). Which of...
Med Lett Drugs Ther. 1990 May 18;32(818):49-50 |  Show IntroductionHide Introduction

Flumazenil

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 1992  (Issue 874)
, particularly after long procedures. Profound re-sedation, according to the manufacturer, occurs in 1% to 3 ...
Flumazenil (Mazicon - Roche), a benzodiazepine receptor antagonist, has been approved by the US Food and Drug Administration to reverse the sedative effects of benzodiazepines after anesthesia, sedation for brief surgical or diagnostic procedures, or after benzodiazepine overdosage. The drug does not antagonize opioids, non-benzodiazepine sedatives, or anesthetic drugs.
Med Lett Drugs Ther. 1992 Jul 10;34(874):66-8 |  Show IntroductionHide Introduction

Itraconazole for Onychomycosis

   
The Medical Letter on Drugs and Therapeutics • Jan 19, 1996  (Issue 966)
) and may soon be approved for oral use as well. ACTIVITY — Less than 0.1 µg/ml of itraconazole inhibits ...
Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for treatment of dermatophyte infections of the toenails, with or without fingernail involvement.
Med Lett Drugs Ther. 1996 Jan 19;38(966):5-6 |  Show IntroductionHide Introduction

Umbilical Cord Blood for Bone Marrow Transplantation

   
The Medical Letter on Drugs and Therapeutics • Aug 16, 1996  (Issue 981)
al, Nat Med, 1:1017, 1995; L Lu et al, Cell Transplant, 4:493, 1995). The risk of viral ...
High-dose chemotherapy followed by bone marrow transplantation continues to be widely used in the treatment of malignant diseases (Medical Letter, 37:25, 1995). The source of the transplant has been autologous or allogeneic bone marrow or, more recently, stem and progenitor cells harvested from peripheral blood (Medical Letter, 37:71, 1995). Now, blood taken from the umbilical cord and placenta of a newborn infant is being tried as a source of cells to restore the bone marrow. A single collection of umbilical cord blood contains about as many progenitor cells as most autologous bone...
Med Lett Drugs Ther. 1996 Aug 16;38(981):71-2 |  Show IntroductionHide Introduction

Ardeparin and Danaparoid for Prevention of Deep Vein Thrombosis

   
The Medical Letter on Drugs and Therapeutics • Oct 10, 1997  (Issue 1011)
FOR PREVENTION OF DEEP VEIN THROMBOSIS Average FDA-approved Mol Wt (Da) Dosage Indications Cost 1 12,000 ...
Ardeparin sodium (Normiflo - Wyeth-Ayerst), a low-molecular-weight heparin, and danaparoid sodium (Orgaran - Organon), a heparinoid, have been approved by the FDA for prevention of deep vein thrombosis. Without anticoagulation, deep vein thrombosis occurs in up to 30% of patients after abdominal surgery, and in 40% to 70% of patients after major orthopedic operations on the lower limbs. Danaparoid sodium is approved in the USA only for use in hip replacement. Ardeparin is approved here only for use in knee replacement.
Med Lett Drugs Ther. 1997 Oct 10;39(1011):94-5 |  Show IntroductionHide Introduction